Bayer Aktiengesellschaft (LON:0P6S)
United Kingdom · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 36.84B +60.6% |
| Revenue (ttm) | 39.07B -1.7% |
| Net Income | -1.50B |
| EPS | -1.52 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 9.27 |
| Dividend | 0.10 (0.26%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 179,419 |
| Open | 43.38 |
| Previous Close | 43.48 |
| Day's Range | 43.31 - 44.82 |
| 52-Week Range | 25.79 - 54.00 |
| Beta | 0.84 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Bayer (BAYN) -- Agricultural and Pharmaceutical Growth | Ruffer Total Return International Q3 2026
Bayer (BAYN) -- Agricultural and Pharmaceutical Growth | Ruffer Total Return International Q3 2026
Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart Failur...
Bayer partners with actress Melissa Joan Hart to increase awareness of Lynkuet
Bayer (BAYRY) announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet 60mg capsules, Bayer’s FDA-approved, hormone-free prescription treatment...
Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet® (elinzanetant) 60mg capsules, Bayer's FD...
Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause
Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet (elinzanetant) 60mg capsules, Bayer’s FDA-approved, hormone-free prescript...
Bayer announces FDA acceptance of Kerendia sNDA
Bayer (BAYRY) announced that the FDA accepted the company’s supplemental new drug application, or sNDA, for Kerendia, which is being investigated for the treatment of adults with chronic kidney diseas...
Bayer Moves To Expand KERENDIA Into Chronic Kidney Disease Without Diabetes
(RTTNews) - Bayer (BYR.L) announced that the U.S. FDA has accepted the company's supplemental New Drug Application for KERENDIA, seeking approval to treat adults with chronic kidney disease (CKD) with...
FDA Accepts Bayer's Filing To Expand KERENDIA Use In CKD Without Diabetes
(RTTNews) - Thursday, Bayer (BYR.L) announced that the U.S. FDA has accepted its supplemental New Drug Application (sNDA) for KERENDIA (finerenone) to treat adults with non-diabetic chronic kidney dis...
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company's supplemental New Drug Application (sNDA) for KERENDIA® (fin...
U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for KERENDIA (finerenone), which is being investiga...
Bayer’s CEO cut managers by 70%. Now comes the hard part
Also: All the news and watercooler chat from Fortune.
Bayer To Invest $2.2 Bln In Ohio Pharma Site, To Create 2,100 Jobs
LEVERKUSEN (dpa-AFX) - Bayer (BYR.L, BAY.MI, BAYN.DE) announced that it plans to invest $2.2 billion in a new pharmaceutical manufacturing facility in New Albany, Ohio. The company expects to crea...
Bayer To Invest $2.2 Bln In Ohio Pharma Manufacturing Campus
(RTTNews) - Bayer (BYR.L, BAYRY.PK, BAYZF.PK, BAY.MI, BAYN.DE) announced plans to invest $2.2 billion in a new pharmaceutical manufacturing facility in New Albany, Ohio, expanding its U.S. footprint t...
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
The German company, which said its new site in Ohio will create around 600 jobs, is the latest European drugmaker to invest in the U.S.
Bayer to invest $2.2 billion in new US pharma site
Bayer's pharmaceuticals unit on Friday unveiled plans to invest $2.2 billion in a new manufacturing site in New Albany, Ohio, part of a push to boost the business's US revenue.
Bayer to invest $2.2B in new manufacturing site in New Albany, Ohio
Bayer (BAYRY) announced plans to invest $2.2B in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than $7B in U.S. pharma R&D and manufacturing spend…
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
NEW ALBANY, Ohio--(BUSINESS WIRE)--Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than seven b...
Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle
WHIPPANY, N.J.--(BUSINESS WIRE)--Alka-Seltzer Plus® will relaunch in 2026 as Alka-Seltzer™ Cold, introducing a more intuitive brand architecture, simplified packaging and value-focused options designe...
Bayer faces trial test of remaining Roundup claims after US Supreme Court win
Attorneys for three cancer patients told a Missouri jury on Tuesday that Bayer's Monsanto unit failed to adequately test its Roundup weedkiller before selling it, starting a trial that could help de...
MiraSOFT Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option
Bayer today announced the launch of MiraSOFT, a new stool softener option from the makers of MiraLAX with the active ingredient docusate sodium designed to help gently soften hard, dry stools and supp...
Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit
A federal judge in Delaware on Monday rejected Pfizer , BioNTech and Moderna's requests to dismiss patent lawsuits filed against them by Bayer's Monsanto unit over the messenger RNA technology used in...
Bayer Gains FDA Priority Review For Lynkuet Label Expansion In Breast Cancer-Related Indication
(RTTNews) - Bayer Aktiengesellschaft (BAYN.DE) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Revie...
Bayer: FDA Grants Priority Review To Lynkuet For New Indication
(RTTNews) - Bayer (BYR.L, BAY.MI, BAYN.DE) announced the FDA has accepted the supplemental New Drug Application and granted Priority Review designation for Lynkuet under investigation for the treatmen...
Bayer announces FDA accepts Lynkuet sNDA for Priority Review
Bayer (BAYRY) announced that the U.S. Food and Drug Administration has accepted the company’s supplemental New Drug Application and granted Priority Review designation for Lynkuet under investigation ...
U.S. FDA Accepts sNDA and Grants Priority Review to Bayer's Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer
WHIPPANY, N.J.--(BUSINESS WIRE)--Today Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Review ...